Aileron Therapeutics Inc (ALRN)

Dec 12, 2024

Aileron Therapeutics to Present at the 8th Annual IPF Summit - The Eastern Progress Online

Dec 12, 2024

Dec 10, 2024

Aileron Therapeutics CEO James Brian Windsor buys $897 in stock By Investing.com - Investing.com Nigeria

Dec 10, 2024

Dec 09, 2024

Aileron Therapeutics CEO James Brian Windsor buys $897 in stock - Investing.com

Dec 09, 2024

Dec 06, 2024

Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - The Eastern Progress Online

Dec 06, 2024

Nov 30, 2024

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Decrease in Short Interest - MarketBeat

Nov 30, 2024

Nov 20, 2024

Aileron Therapeutics Reports Q3 2024 Financial Results - MSN

Nov 20, 2024

Nov 19, 2024

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Citizentribune

Nov 19, 2024

Nov 17, 2024

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 8.7% in October - MarketBeat

Nov 17, 2024

Nov 15, 2024

Aileron Therapeutics Inc (ALRN) Quarterly 10-Q Report - Quartzy

Nov 15, 2024

Nov 14, 2024

Aileron Reports Positive Phase 1b Data for IPF Drug, Shows Strong Biomarker Response | ALRN Stock News - StockTitan

Nov 14, 2024

Nov 13, 2024

Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis - AOL

Nov 13, 2024

Nov 13, 2024

Aileron reports promising phase 1b trial results for IPF treatment - Investing.com

Nov 13, 2024

Nov 13, 2024

Aileron reports promising phase 1b trial results for IPF treatment By Investing.com - Investing.com UK

Nov 13, 2024

Nov 13, 2024

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - Nasdaq

Nov 13, 2024

Nov 01, 2024

Advancium explores ALRN-6924 for pediatric eye cancer treatment - Investing.com India

Nov 01, 2024

Nov 01, 2024

Advancium explores ALRN-6924 for pediatric eye cancer treatment By Investing.com - Investing.com Canada

Nov 01, 2024

Oct 31, 2024

Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma - PR Newswire

Oct 31, 2024

Oct 29, 2024

Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Drops By 14.2% - MarketBeat

Oct 29, 2024

Oct 28, 2024

Constrained Peptide Drugs Market Size, Scope and Share Analysis - InsightAce Analytic

Oct 28, 2024

Oct 14, 2024

Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Increases By 15.8% - MarketBeat

Oct 14, 2024

Oct 13, 2024

ALRNAileron Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 13, 2024

Oct 12, 2024

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis - Lelezard

Oct 12, 2024

Oct 02, 2024

University of Texas Texas AM Investment Management Co. Invests $4.93 Million in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - MarketBeat

Oct 02, 2024

Oct 01, 2024

Nantahala Capital Management LLC Raises Holdings in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - MarketBeat

Oct 01, 2024

Sep 28, 2024

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 13.4% in September - MarketBeat

Sep 28, 2024

Sep 25, 2024

Alumis (NASDAQ:ALMS) Trading 4.8% Higher - MarketBeat

Sep 25, 2024

Sep 25, 2024

Keeping an Eye on Alx Oncology Holdings Inc (ALXO) After Insider Trading Activity - Knox Daily

Sep 25, 2024

Sep 25, 2024

Ready to Jump After Recent Trade: Alx Oncology Holdings Inc (ALXO) - SETE News

Sep 25, 2024

Sep 24, 2024

ALXO stock touches 52-week low at $1.87 amid market challenges - Investing.com

Sep 24, 2024

Sep 24, 2024

Alumis (NASDAQ:ALMS) Shares Gap Down to $11.86 - MarketBeat

Sep 24, 2024

Sep 24, 2024

Market Highlights: Alector Inc (ALEC) Ends on a Low Note at 5.45 - The Dwinnex

Sep 24, 2024

Sep 24, 2024

What is the investor’s view on Alx Oncology Holdings Inc (ALXO)? - US Post News

Sep 24, 2024

Sep 23, 2024

Insider Sale Alert: Aldeyra Therapeutics Inc [ALDX] – Is it Time to sell? - Knox Daily

Sep 23, 2024

Sep 23, 2024

Alector (NASDAQ:ALEC) Shares Down 5.6% - MarketBeat

Sep 23, 2024

Sep 23, 2024

Market Update: Alx Oncology Holdings Inc (ALXO) Sees Negative Movement, Closing at 2.07 - The Dwinnex

Sep 23, 2024

Sep 23, 2024

Keith Johns Joins Allurion's Board Of Directors - MPO-mag

Sep 23, 2024

Sep 23, 2024

HighVista Strategies LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World

Sep 23, 2024

Sep 23, 2024

Taking on analysts’ expectations and winning: Alumis Inc. (ALMS) - SETE News

Sep 23, 2024

Sep 23, 2024

Healius sells Lumus imaging unit to Affinity for USD 657M - Medical Buyer

Sep 23, 2024

Sep 22, 2024

Australia Medical Diagnostics Firm Healius Sells Lumus to Affinity for $657 Million - BNN Bloomberg

Sep 22, 2024

Sep 22, 2024

Renaissance Technologies LLC Sells 800 Shares of Alexander’s, Inc. (NYSE:ALX) - Defense World

Sep 22, 2024

Sep 21, 2024

Alector (NASDAQ:ALEC) Stock Price Up 9% - Defense World

Sep 21, 2024

Sep 21, 2024

1,959,896 Shares in Alumis Inc. (NASDAQ:ALMS) Bought by SR One Capital Management LP - MarketBeat

Sep 21, 2024

Sep 20, 2024

Aileron Therapeutics Inc Inc. (ALRN) Price Performance: The Role of Supply and Demand - The InvestChronicle

Sep 20, 2024

Sep 20, 2024

Closing Bell Recap: Aileron Therapeutics Inc (ALRN) Ends at 2.91, Reflecting a 9.81 Upturn - The Dwinnex

Sep 20, 2024

Sep 19, 2024

Altair Engineering: Rating Downgrade As Near-Term Upside Is Limited (NASDAQ:ALTR) - Seeking Alpha

Sep 19, 2024

Sep 19, 2024

Alumis (NASDAQ:ALMS) Shares Down 2.6% - MarketBeat

Sep 19, 2024

Sep 19, 2024

Alesi Surgical wins FDA clearance for smoke management device and lands new funding - Mass Device

Sep 19, 2024